CoChat

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Open access
Gall, Victor A., Philips, Anne V., Qiao, Na, Clise-Dwyer, Karen, Perakis, Alexander A., Zhang, Mao, Clifton, Guy T., Sukhumalchandra, Pariya, Ma, Qing, Reddy, Sangeetha M., Yu, Dihua, Molldrem, Jeffrey J., Peoples, George E., Alatrash, Gheath, Mittendorf, Elizabeth A. · 2017 · Cancer Research
Cited by 154

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Early-phase clinical trials evaluating CD8+ T cell–eliciting, HER2-derived peptide vaccines administered to HER2+ breast cancer patients in the adjuvant setting suggest synergy between the vaccines and trastuzumab, the mAb targeting the HER2 protein. Among 60 patients enrolled in clinical trials evaluating the E75 + GM-CSF and GP2 + GM-CSF vaccines, there have been no recurrences in patients vaccinated after receiving trastuzumab as part of standard therapy in the per treatment analyses conducted after a median follow-up of greater than 34 months. Here, we describe a mechanism by which this synergy may occur. Flow cytometry showed that trastuzumab facilitated uptake of HER2 by dendritic cells (DC), which was mediated by the Fc receptor and was specific to trastuzumab. In vitro, increased HER2 uptake by DC increased cross-presentation of E75, the immunodominant epitope derived from the HER2 protein, an observation confirmed in two in vivo mouse models. This increased E75 cross-presentation, mediated by trastuzumab treatment, enabled more efficient expansion of E75-specific cytotoxic T cells (E75-CTL). These results demonstrate a mechanism by which trastuzumab links innate and adaptive immunity by facilitating activation of antigen-specific T cells. On the basis of these data, we conclude that HER2-positive breast cancer patients that have been treated with trastuzumab may experience a more robust antitumor immune response by restimulation of T cells with the E75 peptide vaccine, thereby accounting for the improved disease-free survival observed with combination therapy. Cancer Res; 77(19); 5374–83. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-2774

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 154

Metadata

Authors
Gall, V. A., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., Yu, D., Molldrem, J. J., Peoples, G. E., Alatrash, G., & Mittendorf, E. A.
Venue
Cancer Research
Published
2017-10-01
Volume
77
Issue
19
Pages
5374-5383
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2745792339
Cited by
154
References
4
FWCI
3.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2774
The paper
Gall, V. A., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., Yu, D., Molldrem, J. J., Peoples, G. E., Alatrash, G., & Mittendorf, E. A. (2017). Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2774

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.